Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer
June 06, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend, Ph.D., to the...
Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
June 04, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz, RPh, to the...
EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
May 16, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
May 15, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
May 08, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created...
Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
May 07, 2018 08:00 ET
|
Dare Bioscience, Inc.
Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual...
Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
April 30, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the...
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
April 25, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
April 11, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman, M.D., to...
Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
April 02, 2018 16:05 ET
|
Dare Bioscience, Inc.
-Conference Call and Webcast Today, April 2nd, at 4:30 PM Eastern Time- SAN DIEGO, April 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s...